A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
Clinical trial NCT00001052 · COMPLETED
Trial details
- NCT number
- NCT00001052
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Enrollment
- 110
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.